The S165D mutation, which introduces a negative charge as the phosphorylation does, caused secretion of HDGF.46 Therefore, the phosphorylation on HDGF S165 is a valid target for cancer therapy based on kinase inhibitors. This evidence concerns the gene HDGF and cancer.